A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel ...

Boehringer Ingelheim’s busy year of dealmaking is showing no signs of slowing, with the German pharma now turning to established partner CDR-Life for a new trispecific autoimmune antibody. | ...

After discussions with the FDA, Nuvation disclosed that it has “decided not to pursue a head-to-head randomized study of safusidenib against vorasidenib to support approval in non-enhancing grade 2 ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into ...

Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune ...

Olympus has issued updated corrective action related to the 2023 recall of more than 17,600 bronchoscopes that included flexible, fiber-optic systems and video-camera-equipped devices used to observe ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

Tempero Bio has hit the brakes on a phase 2-stage alcohol use disorder (AUD) candidate while the biotech considers its ...

Roche may have been exploring ways to shuttle drugs to the brain for well over a decade, but that’s not stopping the pharma from ...

TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid ...

Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales ...